Figure S5.

Cardiac outcomes following treatment with STING inhibitors. (A and B) qRT-PCR for expression of Irf7 (A) and Cxcl10 (B) in cardiac fibroblasts 28 d after cardiac RT or sham and 7 d of treatment with STING antagonist C-176 or vehicle; N = 2–3 mice per condition; two independent experiments were performed. (C) FS as measured by echocardiography in Sting^+/+ mice 3 mo after cardiac RT or sham treatment and subsequent treatment with either STING antagonist H-151 or vehicle until the time of echocardiography. (D and E) FS (D) and LVED (E) of Sting^+/+ mice 14 d after completing 5 wk doses of doxorubicin or vehicle and concurrent H-151 of vehicle until the time of echocardiography. In D, N = 8–10 mice per condition, experiment performed once. In E, N = 5 mice per condition. *P < 0.05, **P < 0.01, ***P < 0.001, two tailed T test.